Metoprolol Tartrate Dawa

Metoprolol, the active ingredient in Metoprolol Tartrate Dawa, is a beta blocker presented as an injectable solution for intravenous use. It is employed to lower elevated blood pressure, relieve angina pectoris, and improve outcomes after myocardial infarction and in heart failure patients. It reduces heart rate, myocardial contractility and cardiac output, providing cardiovascular protection in a range of acute and chronic conditions.

GNH USA supplies Metoprolol Tartrate Dawa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide with reliable, quality‑assured products.

Metoprolol is a selective β1‑adrenergic blocker used in several cardiovascular conditions.

Hypertension: lowers systolic and diastolic pressure by decreasing heart rate and cardiac output. Angina pectoris: alleviates chest pain by reducing myocardial oxygen demand. Acute myocardial infarction: improves survival by limiting infarct size and reducing arrhythmias. Heart failure: enhances left‑ventricular function and reduces hospitalisation risk. Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other tachyarrhythmias.

Metoprolol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Dizziness or light‑headedness, especially on standing. - Bradycardia: slower than normal heart rate. - Cold extremities: reduced peripheral circulation. - Headache. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical intervention. - Marked hypotension leading to syncope. - Bronchospasm or worsening asthma symptoms. - Acute heart failure decompensation. - Allergic reactions such as rash, angioedema or anaphylaxis. - Cardiogenic shock in rare cases.

When using Metoprolol, clinicians should observe several safety considerations to minimise risk.

Assess cardiac function before initiating: obtain baseline ECG and evaluate heart rate. Monitor blood pressure and heart rate regularly: adjust dose if excessive bradycardia or hypotension occurs. Use caution in patients with asthma or chronic obstructive pulmonary disease: β1 selectivity may not fully prevent bronchospasm. Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension or tachycardia. Adjust dose in renal or hepatic impairment: reduced clearance may require lower dosing. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metoprolol interacts with several drug classes; clinicians should review patient medication lists carefully.

Major Interactions (Avoid): - Concomitant use with other β‑blockers: additive negative chronotropic effects may cause severe bradycardia. - Calcium channel blockers verapamil or diltiazem: combined AV‑node depression can precipitate heart block. - Antiarrhythmic agents class IA (e.g., quinidine) or class III (e.g., amiodarone): increased risk of conduction disturbances.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may attenuate the antihypertensive effect of Metoprolol. - Diuretics (especially thiazides): additive blood pressure lowering; monitor electrolytes. - Antidepressants such as SSRIs: may enhance bradycardia; observe heart rate. - Antidiabetic medications: β‑blockade can mask hypoglycaemia symptoms; adjust monitoring.